The Hidden Risks of Poor Risk Assessment & Weak Validation Strategy
1. Introduction — The Root Cause Nobody Wants to Admit
In a recent consulting project with a South American pharmaceutical manufacturer, Zamann Pharma Support was called to help validate a new Purified Water (PW) system. What we found was not a technical failure — it was a strategic failure.
The system had solid equipment and a qualified vendor — but no solid risk assessment. Validation parameters were adopted without clear justification. “Worst case conditions” were never truly challenged. The system was validated on paper — but not in reality.
This is a recurring global issue: companies validate equipment, not risk. The result? Rework, findings during inspections, delays, and budget overruns.
2. The Real Problem: Weak Validation Strategy
When risk assessment is done merely to “fill a requirement,” the validation strategy becomes reactive, not preventive. In the client case, we found:
- Critical parameters chosen without justification
- No rationale for microbial limits or TOC values
- No flow velocity rationale (e.g., 1 m/s minimum to prevent biofilm)
- No lifecycle strategy — only qualification documents
This led to a major system re-assessment — delaying validation by months and increasing costs.
3. Quick Self-Diagnostic — Are You At Risk?
Give 1 point for each “Yes”:
- Acceptance criteria scientifically justified?
- Worst-case scenarios tested and documented?
- Risk assessment aligned with PQ protocol?
- Flow velocity rationale documented?
- Microbial parameters linked to pharmacopoeia?
- Question Yes/No Periodic Review includes risk re-evaluation?
Score Interpretation
- 0–2 → Acceptable, but vulnerable
- 3–4 → High regulatory exposure
- 5–6 → Validation unlikely to withstand inspection
4. Compliance Clarity — What Regulators Expect
Regulatory Source Key Expectation
- EMA Annex 15 Risk-based validation approach required
- ISPE Baseline Guide Documented justification for design parameters
- FDA CSA Guidance Focus on process risk, not paperwork
- ICH Q9 Risk assessment must support lifecycle approach
External References:
- https://www.ema.europa.eu/
- https://ispe.org/
- https://www.fda.gov/regulatory
5. What to Do Now — Your Action Plan
- ✔ Define a Risk-Based Validation Strategy (RBVS)
- ✔ Create traceability: URS → Risk Assessment → Test Plan → PQ
- ✔ Challenge the system under worst-case conditions
- ✔ Document all rationales — before equipment validation begins
- ✔ Schedule risk-based periodic reviews
6. Final Leadership Thought
Validation is not a document.
It is a decision-making framework.
If risk is poorly defined, validation becomes a formality — not protection.
